Sewart, E., Turner, N. L., Conroy, E., Cutress, R., Skillman, J., Whisker, L., Thrush, S., Barnes, N., Holcombe, C., Potter, S. (2021). Patient-reported outcomes of immediate implant-based breast reconstruction with and without biological or synthetic mesh. *BJS Open, 5*(1), [zraa063]. https://doi.org/10.1093/bjsopen/zraa063

Publisher's PDF, also known as Version of record

License (if available): CC BY

Link to published version (if available): 10.1093/bjsopen/zraa063

Link to publication record in Explore Bristol Research

PDF-document

This is the final published version of the article (version of record). It first appeared online via Oxford University Press at https://doi.org/10.1093/bjsopen/zraa063. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Patient-reported outcomes of immediate implant-based breast reconstruction with and without biological or synthetic mesh

E. Stewart¹, N. L. Turner¹, E. J. Conroy², R. I. Cutress³, J. Skillman⁴, L. Whisker⁵, S. Thrush⁶, N. Barnes⁷, C. Holcombe⁸ and S. Potter†¹,³,⁹*, on behalf of the implant Breast Reconstruction Evaluation (iBRA) Steering Group and the Breast Reconstruction Research Collaborative†¹

¹Population Health Sciences, Bristol Centre for Surgical Research, Bristol Medical School, Bristol, UK
²Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
³Cancer Sciences Unit, Faculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, UK
⁴Department of Plastic Surgery, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
⁵Nottingham Breast Institute, Nottingham University Hospitals NHS Trust, Nottingham, UK
⁶Breast Unit, Worcester Royal Hospital, Worcester, UK
⁷Nightingale Breast Unit, Manchester University NHS Foundation Trust, Manchester, UK
⁸Linda McCartney Centre, Royal Liverpool and Broadgreen University Hospital, Liverpool, UK
⁹Bristol Breast Care Centre, North Bristol NHS Trust, Bristol, UK

†Members of the iBRA Steering Group and Breast Reconstruction Research Collaborative may be found under the heading Collaborators

Abstract

Background: Biological and synthetic meshes may improve the outcomes of immediate implant-based breast reconstruction (IBBR) by facilitating single-stage procedures and improving cosmesis. Supporting evidence is, however, limited. The aim of this study was to explore the impact of biological and synthetic mesh on patient-reported outcomes (PROs) of IBBR 18 months after surgery.

Methods: Consecutive women undergoing immediate IBBR between February 2014 and June 2016 were recruited to the study. Demographic, operative, oncological and 3-month complication data were collected, and patients received validated BREAST-Q questionnaires at 18 months. The impact of different IBBR techniques on PROs were explored using mixed-effects regression models adjusted for clinically relevant confounders, and including a random effect to account for clustering by centre.

Results: A total of 1470 participants consented to receive the questionnaire and 891 completed it. Of these, 67 women underwent two-stage submuscular reconstructions. Some 764 patients had a submuscular reconstruction with biological mesh (495 women), synthetic mesh (95) or dermal sling (174). Fourteen patients had a prepectoral reconstruction. Compared with two-stage submuscular reconstructions, no significant differences in PROs were seen in biological or synthetic mesh-assisted or dermal sling procedures. However, patients undergoing prepectoral IBBR reported better satisfaction with breasts (adjusted mean difference +5.08, 95 per cent c.i. 1.65 to11.61; P = 0.009). PROs were similar to those in the National Mastectomy and Breast Reconstruction Audit 2008–2009 cohort, which included two-stage submuscular procedures only.

Conclusion: This study found no difference in PROs of subpectoral IBBR with or without biological or synthetic mesh, but provides early data to suggest improved satisfaction with breasts following prepectoral reconstruction. Robust evaluation is required before this approach can be adopted as standard practice.

Introduction

Over 2 million women worldwide are diagnosed with breast cancer each year¹, approximately 40 per cent of whom undergo mastectomy as the primary surgical treatment for their disease²⁻⁴. The UK National Institute for Health and Care Excellence recommends that all women undergoing mastectomy should be offered immediate breast reconstruction to minimize the negative impact of surgery on their quality of life (QoL)⁵⁻⁷, and approximately 21 per cent of women in the UK undergoing mastectomy elect to have immediate reconstruction⁶. Currently, implant-based procedures are the most commonly performed reconstructive technique in both the UK⁵ and the USA⁸.

Traditionally, implant-based breast reconstruction (IBBR) has required two sequential operations to achieve placement of a definitive implant in a subpectoral pocket⁹.¹⁰ At the first procedure, a tissue expander is placed under the pectoralis major muscle. A series of saline injections over several weeks are used to increase the expander volume gradually, a process that is
time-consuming and may cause discomfort for the patient. Once the submuscular pocket is sufficiently large, the expander is removed and replaced with a fixed-volume implant, committing the patient to a second operation and associated risks.

Since the early 2000s, new techniques have emerged that allow the creation of a larger submuscular pocket that can accommodate a definitive implant at the first operation. These single-stage techniques involve the use of an ‘internal bra’ or sling between the lower edge of the pectoralis muscle and the chest wall, extending the subpectoral pocket. This sling can be formed from a biological material (such as acellular dermal matrix (ADM), synthetic mesh (for example titanium-coated polypropylene) or a dermal sling (using de-epithelialized skin). In addition to no necessity for a second procedure, these techniques produce better cosmetic outcomes by improving inframammary fold control and lower pole projection. More recently, prepectoral techniques have emerged, which involve wrapping the implant in biological or synthetic mesh and placing it on top of the pectoralis muscle. Avoiding muscle disruption may reduce postoperative pain and prevent distressing breast animation (the upwards movement of the implant seen when the pectoralis muscle contracts).

Biological and synthetic mesh-assisted IBBR techniques have been introduced and widely adopted into practice. They improve outcomes for patients, but little high-quality evidence supports these proposed benefits. In particular, patient-reported outcomes (PROs) are lacking. One RCT of 142 patients compared PROs in patients undergoing two-stage IBBR and single-stage reconstruction with mesh (ADM) using the validated BREASt-Q questionnaire. Despite higher complication rates in patients undergoing ADM-assisted IBBR, including reoperation and implant loss, this multicentre Dutch study found no difference in PROs 1 year after placement of the definitive implant. Reasons for this are unclear, but most patients in the ADM group who experienced implant loss went on to have a secondary reconstruction and did not complete PRO questionnaires until after the study had been done. A large North American multicentre cohort study of 1297 patients, comparing outcomes in women undergoing two-stage reconstructions with and without ADM, however, reported no difference in either clinical outcomes or PROs 2 years after reconstruction. Analysis of outcomes in patients undergoing single (99 women) and two-stage (1328) reconstructions in the same cohort also demonstrated no difference in clinical outcomes or PROs at 2 years. The use of mesh, however, was not reported, and the study was potentially underpowered to detect a difference between the groups. Recent studies have reported the PROs of biological and synthetic mesh-assisted prepectoral reconstructions. These studies, however, were small, retrospective, and conducted at either a single or two centres, limiting their generalizability to other settings. Uncertainty therefore remains regarding the impact of the use of biological and synthetic mesh on PROs, and further work is needed.

The IBRA (Implant Breast Reconstruction Evaluation) study is a four-phase study aiming to inform the feasibility, design and conduct of a future trial in immediate IBBR. Phase 2, a UK prospective multicentre cohort study, explored the clinical and patient-reported outcomes of different approaches to immediate IBBR with and without biological and synthetic mesh. The short-term safety outcomes have been published elsewhere and showed no evidence of a difference in key complications between different approaches to IBBR. High-quality PRO data are therefore vital to support the ongoing use of mesh-assisted techniques, and to help patients make informed decisions regarding surgery. This study reports the 18-month PROs of IBBR from patients in the IBRA cohort study and explores the impact of different IBBR techniques, performed with and without biological and synthetic mesh, on patient satisfaction and QoL.

Methods

The IBRA study prospectively recruited consecutive women aged 16 years or above undergoing immediate IBBR for malignancy or risk reduction between 1 February 2014 and 30 June 2016. Patients undergoing skin- or nipple-sparing mastectomy followed by immediate IBBR were eligible for inclusion. All UK breast or plastic surgical units performing IBBR were invited to participate via the UK Trainee Collaborative Research Network, the Association of Breast Surgery, and the British Association of Plastic, Reconstructive and Aesthetic Surgeons. The protocol was published in 2016. Any IBBR technique could be used, including standard two-stage procedures, submuscular reconstructions with biological or synthetic mesh or dermal sling, and prepectoral reconstructions. As the study aimed to describe current practice and inform future research, procedural details were recorded but no restrictions were placed on the techniques used. Product choice, implant positioning and use of laminar flow, antibiotics and drains were according to local policy or surgeon preference. Patients were excluded from the study if undergoing delayed reconstruction, implant reconstruction in combination with an autologous flap, or revision of a previously performed breast reconstruction. Patients undergoing primary implant reconstruction recruited to the study who subsequently required revision remained eligible for inclusion.

Eligible patients were identified prospectively from clinics, multidisciplinary team (MDT) meetings and theatre lists. Demographic, operative, oncological and 3-month complication data were collected by the team by clinical or case note review. Patients who consented received electronic or postal questionnaires, according to their preference, at 3 and 18 months after surgery. The 3-month questionnaire included questions regarding satisfaction with information, pain, postoperative complications and adjuvant treatment. These results have been reported elsewhere. The 18-month questionnaire assessed patient satisfaction and QoL using the BREASt-Q as per the methodology of the UK National Mastectomy and Breast Reconstruction Audit (NMBRA). Reminders were sent after 1 month if no response had been received. Follow-up was complete in December 2017. Anonymized data were recorded using REDCap (www.projectredcap.org), a secure online database.

Study governance and consent to participate

Ethical approval was not required, as defined by the Health Research Authority decision tool. Local audit approval was obtained for each centre before study recruitment was commenced. Clinical and PRO data were collected as recommended by guidelines for good practice.

Patients were approached for written consent to receive questionnaires by members of the clinical team, either in clinic or during their hospital stay, according to local study team preference. This was consistent with the methodology used in the NMBRA. Where consent was obtained, patient contact details were sent securely to the coordinating centre and questionnaires were distributed centrally to allow accurate follow-up and minimize missing data.
Patient population
Women from the iBRA cohort who returned the 18-month PROs questionnaire were eligible for inclusion in this analysis. Patients were excluded if no data regarding the specific type of IBBR performed had been recorded or the completed 18-month PRO questionnaire had not been received.

Outcomes
This was the planned analysis of the 18-month PROs of patients undergoing IBBR with and without mesh in the iBRA cohort study. The PROs were assessed using the validated BREAST-Q postoperative reconstruction module (version 1). The BREAST-Q is a validated questionnaire developed robustly using Rasch methodology, for use in a breast reconstruction population, and includes five domains: satisfaction with breasts; satisfaction with outcome; physical well-being (chest); psychosocial well-being; and sexual well-being. This was selected as it assessed key PRO domains included in the reconstructive breast surgery core outcomes set. The 18-month questionnaire also included a single-item assessment of overall satisfaction with reconstructive outcome on a five-point Likert scale (excellent, very good, good, fair and poor), as per the 2008–2009 UK NMBRA.

The study was registered as ISRCTN37664281 and has been reported according to STROBE guidelines. Short-term safety outcomes were published in 2019.

Statistical analysis
Patients were categorized by the reconstructive technique used: standard two-stage submuscular; submuscular with biological mesh, synthetic mesh or dermal sling; prepectoral; and other. Patients who received different techniques per breast were included in the ‘other’ category.

Simple summary statistics were used to describe patient demographics, procedures performed to the breast and axilla, oncological data, 3-month complications, and 18-month PROs across the patient groups. Comparisons were made between the groups of patients who did and did not consent to receive questionnaires; those who returned the 18-month questionnaire and non-responders; and between groups of patients who underwent different types of IBBR. Categorical data are summarized by counts and percentages, and continuous data by median (i.q.r.; range) values.

Questionnaire responses for the BREAST-Q domains were summed and transformed according to the developers’ instructions using the specifically designed Q-Score software. This generated a score from 0 to 100 for each domain, where higher scores indicate greater patient satisfaction or QoL. BREAST-Q scores were treated as continuous variables. For the purpose of analysis, the single-item overall outcome score was dichotomized into ‘excellent’ or ‘very good’ and ‘good, fair or poor’. Median (i.q.r.; range) scores for each BREAST-Q domain were calculated, alongside percentages rating the overall outcome as ‘excellent’ or ‘very good’ for each group in order to compare the findings against those reported in the NMBRA and published national quality standards.

The effect of different approaches to IBBR with and without biological and synthetic mesh on each outcome domain were explored using multivariable mixed-effects linear and logistic regression models, including a random effect to account for potential clustering by centre. The reference group was two-stage submuscular reconstruction without mesh. Models were adjusted for clinically relevant confounders identified by the study steering group, based on the literature and clinical expertise. These confounders were: age, BMI, smoking status, ASA grade, indication (malignancy, risk reduction or both), bilateral surgery, nipple-sparing versus other mastectomy types, 3-month complications (infection, implant loss, readmission or reoperation), axillary surgery, postoperative radiotherapy, and adjuvant chemotherapy and endocrine therapy. A complete case analysis was undertaken, and robust residual estimates were used to ensure the assumptions of the regression models were not violated.

Results
The iBRA study recruited 2108 patients from 81 centres between 1 February 2014 and 30 June 2016. Consent to receive postoperative questionnaires was gained from 1470 women (69.7 per cent), and 891 of women (60.6 per cent) returned them. Of the patients who returned the questionnaire, 12 (1.3 per cent) were excluded as details of the type of IBBR performed were not reported, 879 women were therefore eligible for inclusion in the analysis.

Participant demographics
Patients who consented to receive PROs questionnaires were demographically representative of the overall iBRA cohort (Table S1). However, the 891 patients who returned the 18-month questionnaire were less likely than 579 non-responders to smoke (7.0 versus 14.2 per cent respectively; P < 0.001) or to have experienced complications, in particular reoperation (16.8 versus 22.3 per cent; P = 0.008) and implant loss (5.7 versus 12.6 per cent; P < 0.001) at 3 months. Questionnaire response rates were similar for different types of IBBR. Full cohort demographics by PRO status (consented, not consented; responders and non-responders) are summarized in Table S1.

The median age of patients who returned the questionnaire was 50 (i.q.r. 45–58) years. Median BMI was 24.6 (i.q.r. 23–28.0) kg/m², highest in the group of patients who had dermal sling reconstructions (median 28.6 [range 13.3–42.6] kg/m²). Sixty-two patients (7.0 per cent) were current smokers and 56 (6.3 per cent) had received previous radiotherapy to the ipsilateral breast. Some 732 patients (82.2 per cent) underwent mastectomy for malignancy in at least one breast, and 157 patients (17.6 per cent) had risk reduction surgery only (Table 1).

The majority of patients had a submuscular reconstruction using biological mesh (495 women, 55.6 per cent). One in five (174, 19.5 per cent) received submuscular IBBR with a dermal sling, and a smaller proportion (95, 10.7 per cent) underwent a submuscular reconstruction using synthetic mesh. Of the patients undergoing mesh-assisted IBBR, the majority (500 of 590, 84.7 per cent) had a planned single-stage procedure. Only 67 patients (7.5 per cent) received traditional two-stage submuscular reconstructions. Fourteen women (1.6 per cent) had mesh-assisted prepectoral reconstructions (all single stage), which were introduced towards the end of the study recruitment period at a small number of centres (n = 5) (Table 2). Thirty-four patients (3.8 per cent) underwent other techniques (29, 3.3 per cent) or different techniques per breast (5, 0.6 per cent), and details of the type of IBBR performed was not reported for 12 women (1.3 per cent). Further details of patients who had other types of IBBR, and those in whom details were not reported, are summarized in Tables S2–S5. Of the 732 patients with malignancy, 574 (78.4 per cent) also underwent axillary surgery, and approximately one-third were recommended adjuvant chemotherapy (242, 33.1 per cent) or radiotherapy (207, 28.3 per cent) (Table 5).
| Table 1 General demographics of patients who returned the 18-month questionnaire, by type of implant-based breast reconstruction |
|---------------------------------------------------------------|
| **Age** | All patients' (*n* = 891) | Submuscular (*n* = 67) | Dermal sling (*n* = 174) | Biological mesh (*n* = 495) | Synthetic mesh (*n* = 95) | Prepectoral implant (*n* = 14) |
| Median (i.q.r.; range) | 50 (45–58; 16–83) | 50 (44–59; 16–73) | 53 (46–60; 24–81) | 50 (44–58; 25–78) | 52 (45–60; 25–83) | 50 (37–52; 19–71) |
| Not known | 5 (0.6) | 0 (0) | 1 (0.6) | 3 (0.6) | 0 (0) | 0 (0) |
| **BMI (kg/m²)** | Median (i.q.r.; range) | 24.6 (22.3–28.0; 16.4–42.6) | 23.1 (21.2–25.5; 17.0–40.7) | 28.6 (25–32.3; 13.3–42.6) | 23.9 (21.8–26.2; 16.4–39.0) | 25 (22.6–29.0; 17.9–36.8) | 24.6 (23.3–25.6; 8.7–35.3) |
| Not obese (<30) | 706 (79.2) | 54 (81) | 100 (57.5) | 441 (89.1) | 71 (75) | 13 (93) |
| Obese (≥30) | 138 (15.5) | 9 (13) | 67 (38.5) | 33 (6.7) | 19 (20) | 1 (7) |
| Not known | 47 (5.3) | 4 (6) | 7 (4.0) | 21 (4.2) | 5 (5) | 0 (0) |
| **Smoking status** | | | | | | | |
| Non-smoker | 719 (80.7) | 51 (76) | 140 (80.5) | 402 (81.2) | 71 (75) | 13 (93) |
| Ex-smoker | 99 (11.1) | 10 (15) | 20 (11.5) | 51 (10.3) | 11 (12) | 4 (29) |
| Current smoker | 62 (7.0) | 6 (9) | 11 (6.3) | 38 (7.7) | 5 (5) | 1 (7) |
| Nicotine replacement | 4 (0.4) | 0 (0) | 2 (1.1) | 2 (0.4) | 0 (0) | 0 (0) |
| Not known | 7 (0.8) | 0 (0) | 1 (0.6) | 2 (0.4) | 0 (0) | 0 (0) |
| **Diabetes** | | | | | | | |
| Yes | 20 (2.2) | 0 (0) | 10 (5.7) | 5 (1.0) | 3 (3) | 0 (0) |
| No | 863 (96.9) | 65 (97) | 162 (95.1) | 488 (98.6) | 91 (96) | 14 (100) |
| Not known | 8 (0.9) | 1 (1) | 2 (1.1) | 2 (0.4) | 1 (8) | 0 (0) |
| **ASA grade** | | | | | | | |
| I | 528 (59.3) | 35 (52) | 79 (45.4) | 322 (65.1) | 62 (65) | 8 (57) |
| II | 336 (37.7) | 29 (43) | 87 (50.0) | 166 (33.5) | 30 (32) | 6 (43) |
| III | 20 (2.2) | 3 (4) | 8 (4.6) | 5 (1.0) | 2 (2) | 0 (0) |
| IV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Not known | 7 (0.8) | 0 (0) | 2 (0.4) | 1 (1) | 0 (0) | 0 (0) |
| **Indication** | | | | | | | |
| Malignancy | 732 (82.2) | 57 (85) | 141 (81.0) | 412 (83.2) | 78 (82) | 9 (64) |
| Risk reduction | 157 (17.6) | 10 (15) | 33 (19.0) | 83 (16.8) | 17 (18) | 5 (36) |
| Not known | 2 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| **Previous radiotherapy to ipsilateral breast** | | | | | | | |
| Yes | 56 (6.3) | 3 (4) | 8 (4.6) | 35 (7.1) | 6 (6) | 0 (0) |
| No | 832 (93.4) | 64 (96) | 166 (95.4) | 460 (92.9) | 87 (92) | 14 (100) |
| Not known | 3 (0.3) | 0 (0) | 0 (0) | 0 (0) | 2 (2) | 0 (0) |
| **Neoadjuvant chemotherapy** | | | | | | | |
| Yes | 82 (9.2) | 7 (10) | 21 (12.1) | 41 (8.3) | 8 (8) | 1 (7) |
| No | 799 (89.7) | 59 (88) | 152 (87.4) | 449 (90.7) | 85 (89) | 13 (93) |
| Not known | 10 (1.1) | 1 (1) | 1 (0.6) | 5 (1.0) | 2 (2) | 0 (0) |
| **Neoadjuvant endocrine therapy** | | | | | | | |
| Yes | 36 (4.0) | 4 (6) | 9 (5.2) | 18 (3.6) | 1 (1) | 0 (0) |
| No | 847 (95.1) | 63 (94) | 163 (93.7) | 474 (95.8) | 93 (98) | 14 (100) |
| Not known | 8 (0.9) | 0 (0) | 2 (1.1) | 3 (0.6) | 1 (1) | 0 (0) |

Values in parentheses are percentages unless indicated otherwise. *Details of patients with ‘other’ and ‘not known’ types of implant reconstruction are summarized in Table S2.*
|Operative details and 3-month outcomes for patients who returned the 18-month questionnaire|
|---|
|**Laterality of procedure**|
|All patients* (n = 891) | Submuscular (n = 67) | Dermal sling (n = 174) | Biological mesh (n = 495) | Synthetic mesh (n = 95) | Prepectoral (n = 14) |
|Unilateral | 669 (75.1) | 51 (76) | 134 (77.0) | 379 (76.6) | 66 (69) | 8 (57) |
|Bilateral | 220 (24.7) | 16 (24) | 40 (23.0) | 116 (23.4) | 29 (31) | 6 (43) |
|Not known | 2 (0.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|**Planned procedure**|
|Single-stage reconstruction | 700 (78.6) | 26 (39) | 121 (69.5) | 423 (85.5) | 77 (81) | 14 (100) |
|Two-stage reconstruction | 184 (20.7) | 40 (60) | 51 (29.3) | 69 (13.9) | 17 (18) | 0 (0) |
|Different approach per breast | 7 (0.8) | 1 (1) | 2 (1.1) | 3 (0.6) | 1 (1) | 0 (0) |
|Not known | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|**Type of mastectomy**|
|Skin-sparing | 492 (55.2) | 46 (69) | 40 (23.0) | 325 (65.7) | 60 (63) | 6 (43) |
|Skin and nipple-sparing | 213 (23.9) | 13 (19) | 8 (4.6) | 143 (28.9) | 29 (31) | 8 (57) |
|Reduction (Wise) pattern | 162 (18.2) | 1 (1) | 124 (71.3) | 18 (3.6) | 4 (4) | 0 (0) |
|Other | 8 (0.9) | 5 (7) | 1 (0.6) | 1 (0.2) | 1 (1) | 0 (0) |
|Different approach per breast | 3 (0.3) | 2 (3) | 1 (0.6) | 7 (1.4) | 1 (1) | 0 (0) |
|Not known | 6 (0.7) | 0 (0) | 0 (0) | 1 (0.2) | 1 (1) | 0 (0) |
|**Incision**|
|Periareolar | 49 (5.5) | 3 (4) | 1 (0.6) | 37 (7.5) | 5 (5) | 1 (7) |
|Lateral | 80 (9.0) | 3 (4) | 2 (1.1) | 56 (11.3) | 14 (15) | 3 (21) |
|Inframammary | 93 (10.4) | 7 (10) | 2 (1.1) | 65 (13.1) | 9 (9) | 4 (29) |
|Elliptical, removing NAC | 405 (45.5) | 44 (66) | 2 (1.1) | 293 (59.2) | 51 (54) | 5 (36) |
|Wise pattern | 215 (24.1) | 2 (3) | 161 (92.5) | 26 (5.3) | 6 (6) | 0 (0) |
|Other | 36 (4.0) | 10 | 5 (2.9) | 13 (2.6) | 8 (8) | 1 (7) |
|Different approach per breast | 7 (0.8) | 1 (1) | 0 (0) | 4 (0.8) | 1 (1) | 0 (0) |
|Not known | 6 (0.7) | 0 (0) | 0 (0) | 1 (0.2) | 1 (1) | 0 (0) |
|**Mastectomy weight (g)**|
|Median (i.q.r.; range) | 380.5 (250–582; 0–1802) | 275 (146–433; 0–1538) | 665 (507–903; 140–1802) | 322 (225–460; <1–1236) | 390 (261–557; 83–1164) | 342 (250–455; 167–750) |
|Not known | 45 (5.1) | 4 (6) | 5 (2.9) | 22 (4.4) | 4 (4) | 1 (7) |
|**Prosthesis used**|
|Fixed-volume implant | 212 (23.8) | 18 (27) | 41 (23.6) | 121 (24.4) | 20 (21) | 0 (0) |
|Combined expander or implant | 521 (58.5) | 18 (27) | 84 (48.3) | 318 (64.2) | 61 (64) | 13 (93) |
|Temporary expander | 148 (16.6) | 31 (46) | 48 (27.6) | 54 (10.9) | 13 (14) | 0 (0) |
|Different approach per breast | 3 (0.3) | 0 (0) | 0 (0) | 2 (0.4) | 0 (0) | 0 (0) |
|Not known | 7 (0.8) | 0 (0) | 1 (0.6) | 0 (0) | 1 (1) | 1 (7) |
|**Implant size (ml)**|
|Median (i.q.r.; range) | 375 (290–450; 100–800) | 317.5 (190–400; 100–615) | 480 (410–555; 215–690) | 352.5 (270–420; 120–650) | 410 (295–470; 135–800) | 425 (340–450; 290–685) |
|Not known | 375 (42.1) | 49 (73) | 91 (52.3) | 179 (36.2) | 34 (36) | 2 (14) |
|**Axillary surgery**|
|None | 234 (26.3) | 18 (27) | 43 (24.7) | 129 (26.1) | 28 (29) | 5 (36) |
|SNB | 383 (43.0) | 24 (36) | 75 (43.1) | 221 (44.6) | 40 (42) | 6 (43) |
|Axillary sample | 10 (1.1) | 3 (5) | 0 (0) | 7 (1.4) | 1 (1) | 0 (0) |
|Axillary clearance | 88 (9.9) | 9 (13) | 19 (30.9) | 46 (9.3) | 8 (8) | 2 (14) |
|SNB and ANC | 18 (2.0) | 1 (1) | 5 (2.9) | 9 (2.8) | 2 (2) | 0 (0) |
|Previous axillary staging | 79 (8.9) | 7 (10) | 15 (8.6) | 47 (9.5) | 5 (5) | 0 (0) |
|Different approach per breast | 75 (8.4) | 6 (9) | 17 (9.8) | 36 (7.3) | 11 (12) | 1 (7) |
|Not known | 4 (0.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|**Duration of surgery (min)**|
|Median (i.q.r.; range) | 180 (150–210; 60–480) | 150 (120–190; 60–380) | 180 (150–240; 75–480) | 180 (150–210; 69–445) | 171 (142–190; 70–330) | 180 (150–180; 106–330) |
|Not known | 76 (8.5) | 5 (7) | 8 (4.6) | 47 (9.5) | 3 (3) | 1 (7) |

(continued)
At 3 months, 229 patients (25.7 per cent) had required treatment for postoperative infection, 147 (16.5 per cent) had been readmitted to hospital for a complication, and 51 (5.7 per cent) had experienced implant loss (Table 2). The type of IBRR performed did not appear to be a risk factor for any of the key safety outcomes in the full cohort of patients, details of which have been reported elsewhere\(^\text{13}\).

### Outcomes

The 18-month PROs by type of IBRR performed are summarized in Table 4, alongside the 18-month adjusted outcomes from the NMBRA\(^2\). Most questionnaires were returned with all items completed. The number of sufficiently complete responses to be used for analysis were similar for each domain, with the exception of sexual well-being, which was an optional scale (Table 5).

Across all domains, median BREAST-Q scores and overall outcome ratings were similar in all patient groups, irrespective of the type of IBRR performed, and were largely consistent with the unadjusted mean scores reported in the NMBRA (Table 4)\(^37\). Patients in the iBRA cohort, however, were less satisfied with the overall outcomes of their reconstruction than those in the NMBRA\(^37\).

Mixed-effects linear and logistic regression models were used to evaluate the impact of different approaches to IBRR on BREAST-Q scores (Table 5) and patient rating of overall outcome (Table S6). In this analysis, there was no evidence of an association between type of IBRR performed and differences in satisfaction with outcome, physical well-being, sexual well-being, psychosocial well-being or rating of overall outcome. Patients who had prepectoral reconstructions reported higher scores in the satisfaction with breasts domain (adjusted mean difference in BREAST-Q score \(+\)6.63, 95 per cent c.i. 1.65 to 11.61; \(P = 0.009\)), however, there was no evidence of a difference in scores for any other domain or overall outcome rating in this group.

### Discussion

This large multicentre prospective cohort study of 879 women undergoing immediate IBRR with and without biological or synthetic mesh does not suggest that the addition of mesh improved PROs 18 months after surgery. Furthermore, patient satisfaction and QoL, as measured by the BREAST-Q, were remarkably similar to those reported in the 2007–2008 NMBRA, which included only patients undergoing two-stage IBRR without mesh. Although it is acknowledged that patient expectations of reconstructive surgery may have changed over time, this comparison further suggests that the introduction of mesh-assisted techniques has done little to improve the PROs of IBRR.

Although this study found no evidence to support a PRO benefit associated with biological or synthetic mesh use in subpectoral breast reconstruction, it has generated early data to suggest that prepectoral techniques may improve PROs. Women undergoing prepectoral reconstructions reported greater satisfaction with breasts than those undergoing subpectoral techniques. This difference may be clinically significant as it exceeds the recently reported minimum clinically important difference in BREAST-Q score (4 points)\(^38\). These findings, however, should be interpreted with caution as the prepectoral group was small (14 patients), with the technique introduced late in the recruitment period. Furthermore, prepectoral reconstructions were performed in only 5 of the 81 centres recruiting patients to the study. Their outcomes, therefore, may be biased by the skills and experience of a small group of highly expert operating surgeons, and may
Table 3 Details of malignancy for all patients with cancer who returned the 18-month questionnaire

| Laterality of malignancy          | All patients (n = 732) | Submuscular (n = 57) | Dermal sling (n = 141) | Biological mesh (n = 412) | Synthetic mesh (n = 78) | Prepectoral (n = 9) |
|-----------------------------------|------------------------|----------------------|------------------------|--------------------------|------------------------|---------------------|
| Unilateral                        | 698 (95.4)             | 53 (93)              | 137 (97.2)             | 396 (96.1)               | 71 (91)                | 7 (78)              |
| Bilateral                         | 34 (4.6)               | 4 (7)                | 4 (2.8)                | 16 (3.9)                 | 7 (9)                  | 2 (22)              |
| **Invasive status**               |                        |                      |                        |                          |                        |                     |
| Invasive                          | 513 (70.1)             | 37 (65)              | 92 (65.2)              | 296 (71.8)               | 52 (67)                | 8 (89)              |
| Ductal carcinoma in situ          | 165 (22.5)             | 10 (18)              | 39 (27.7)              | 92 (22.3)                | 18 (23)                | 0 (0)               |
| Different status per breast       | 5 (0.7)                | 0 (0)                | 0 (0)                  | 4 (1.0)                  | 1 (1)                  | 0 (0)               |
| Not known                         | 49 (6.7)               | 10 (18)              | 10 (7.1)               | 20 (4.9)                 | 7 (9)                  | 7 (11)              |
| **Grade**                         |                        |                      |                        |                          |                        |                     |
| Low grade or well differentiated  | 73 (10.0)              | 3 (5)                | 10 (7.1)               | 47 (11.4)                | 10 (13)                | 0 (0)               |
| Intermediate grade or moderately  | 319 (43.6)             | 28 (49)              | 62 (44.0)              | 181 (43.9)               | 27 (35)                | 4 (44)              |
| differentiated                    |                        |                      |                       |                          |                        |                     |
| High grade or poorly differentiated| 273 (37.3)             | 15 (26)              | 57 (40.4)              | 153 (37.1)               | 32 (41)                | 3 (33)              |
| Different per breast              | 13 (1.8)               | 1 (2)                | 2 (1.4)                | 6 (1.5)                  | 2 (3)                  | 1 (11)              |
| Not known                         | 54 (7.4)               | 10 (18)              | 10 (7.1)               | 25 (6.1)                 | 7 (9)                  | 1 (11)              |
| **Size of lesion**                |                        |                      |                        |                          |                        |                     |
| Median (i.q.r.; range)            | 24 (14–45; 0–750)      | 25 (15–50; 2.5–125)  | 30 (15–50; 0–750)      | 22 (14–40; 0–145)        | 28 (14–52; 1.2–106)   | 18 (13.3–31; 9–18)  |
| Not known                         | 63 (8.6)               | 10 (18)              | 15 (10.6)              | 26 (6.3)                 | 8 (10)                 | 1 (11)              |
| **No. of involved nodes (i.q.r.; range)** | 0 (0–0.5; 0–32)     | 0 (0–1; 0–22)        | 0 (0–0.75; 0–12)       | 0 (0–0; 0–32)            | 0 (0–1; 0–19)         | 0 (0–0.75; 0–5)     |
| Not known                         | 56 (7.7)               | 10 (18)              | 9 (6.4)                | 22 (5.3)                 | 8 (10)                 | 1 (11)              |
| **Planned adjuvant chemotherapy**|                        |                      |                        |                          |                        |                     |
| Yes                               | 242 (33.1)             | 25 (44)              | 40 (28.4)              | 135 (32.8)               | 27 (35)                | 5 (56)              |
| No                                | 434 (59.3)             | 22 (39)              | 91 (64.5)              | 252 (61.2)               | 45 (58)                | 3 (33)              |
| Not known                         | 56 (7.7)               | 10 (18)              | 10 (7.1)               | 25 (6.1)                 | 6 (8)                  | 1 (11)              |
| **Planned adjuvant radiotherapy** |                        |                      |                        |                          |                        |                     |
| Yes                               | 207 (28.3)             | 23 (40)              | 40 (28.4)              | 109 (26.5)               | 24 (31)                | 2 (22)              |
| No                                | 470 (64.2)             | 23 (40)              | 91 (64.5)              | 280 (68.0)               | 48 (62)                | 6 (67)              |
| Not known                         | 55 (7.5)               | 11 (19)              | 10 (7.1)               | 23 (5.6)                 | 6 (8)                  | 1 (11)              |
| **Planned adjuvant endocrine therapy** |                    |                      |                        |                          |                        |                     |
| Yes                               | 470 (64.2)             | 31 (54)              | 85 (60.3)              | 271 (65.8)               | 51 (65)                | 8 (89)              |
| No                                | 213 (29.1)             | 16 (28)              | 47 (33.3)              | 122 (29.6)               | 21 (27)                | 0 (0)               |
| Not known                         | 49 (6.7)               | 10 (18)              | 9 (6.4)                | 19 (4.6)                 | 6 (8)                  | 1 (11)              |

Values in parentheses are percentages unless indicated otherwise. †Details of pathology and adjuvant treatment in patients with ‘other’ and ‘not known’ types of implant reconstruction are summarized in Table S4
†Planned adjuvant therapies as per multidisciplinary team recommendation.
### Table 4 Patient-reported outcomes at 18 months by method of reconstruction

|                                | All patients (n = 891) | Submuscular (n = 67) | Dermal sling (n = 174) | Biological mesh (n = 495) | Synthetic mesh (n = 95) | Prepectoral (n = 14) | NMBRA 2008–2009†‡ |
|--------------------------------|------------------------|----------------------|------------------------|--------------------------|------------------------|----------------------|---------------------|
| **Satisfaction with breasts**  | 59 (48–71; 0–100)      | 54.5 (45–73; 11–100) | 58 (47–67; 0–100)      | 61 (48–73; 0–100)        | 56 (47–71; 0–100)      | 63 (48–78; 27–100)  | 55                  |
| n                              | 879                    | 66                   | 173                    | 487                      | 94                     | 14                   |                     |
| **Satisfaction with outcome**  | 67 (55–86; 0–100)      | 67 (55–100; 0–100)   | 74 (55–86; 0–100)      | 73 (55–86; 0–100)        | 67 (61–86; 0–100)      | 74 (61–86; 0–100)   | –                   |
| n                              | 872                    | 66                   | 168                    | 486                      | 93                     | 14                   |                     |
| **Psychosocial well-being**    | 67 (52–86; 0–100)      | 67 (50–92; 14–100)   | 63 (49–82; 0–100)      | 67 (53–86; 0–100)        | 67 (52–86; 0–100)      | 63 (53–100; 28–100) | 65                  |
| n                              | 873                    | 66                   | 168                    | 486                      | 94                     | 14                   |                     |
| **Sexual well-being**          | 46 (33–60; 0–100)      | 49 (32–63; 0–100)    | 41 (29–54; 0–100)      | 47 (34–63; 0–100)        | 50.5 (30.5–63; 0–100)  | 47.5 (26–83; 0–100) | 46                  |
| n                              | 873                    | 47                   | 123                    | 374                      | 68                     | 10                   |                     |
| **Physical well-being**        | 74 (66–85; 13–100)     | 72.5 (66–85; 36–100) | 71 (60–85; 25–100)     | 74 (66–85; 13–100)       | 74 (63–81; 33–100)     | 75.5 (63–85; 36–100) | 75                  |
| n                              | 875                    | 66                   | 170                    | 486                      | 93                     | 14                   |                     |
| **Satisfaction with overall outcome** | 301 (33.8) | 20 (30) | 54 (31.0) | 173 (34.9) | 32 (34) | 4 (29) | 520 (33.9) |
| Excellent                      | 285 (32.0) | 19 (28) | 59 (33.9) | 157 (31.7) | 32 (34) | 5 (36) | 505 (33.0) |
| Very good                      | 161 (18.1) | 16 (24) | 34 (19.5) | 84 (17.0) | 19 (20) | 2 (14) | 288 (18.8) |
| Good                           | 97 (10.9)  | 8 (12)  | 14 (8.0)  | 58 (11.7)  | 8 (8)   | 2 (14) | 145 (9.5)  |
| Fair                           | 38 (4.3)   | 3 (4)   | 9 (5.2)   | 20 (4.0)   | 3 (3)   | 1 (7)  | 74 (4.8)   |
| Poor                           | 9 (1.0)    | 1 (1)   | 4 (2.3)   | 3 (0.6)    | 1 (1)   | 0 (0)  | –          |
| Not known                      | 882        | 66      | 170       | 492        | 94      | 14     | –          |
| n                              | 882        | 66      | 170       | 492        | 94      | 14     | –          |

Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.; range). n indicates the number of patients who completed the relevant part of the questionnaire. †Scores for patients with ‘other’ and ‘not known’ types of implant reconstruction are summarized in Table S5. ‡Unadjusted mean outcome scores from patients in the National Mastectomy and Breast Reconstruction Audit (NMBRA) 2007–2008 cohort who underwent implant-based breast reconstruction.
not be generalizable to the wider reconstructive community. No differences were seen in other BREAST-Q domains, most notably physical well-being, which includes an assessment of arm and chest wall function, and it is possible the observed improvement in satisfaction with breasts may have occurred due to multiple testing. Prepectoral reconstruction has been widely adopted worldwide since the iBRA study, and further work is needed urgently to evaluate robustly both the clinical and patient-reported outcomes of this technique, as data are currently lacking.

This work contributes significantly to the limited published literature assessing PROs of IBBR; however, it has several limitations. First, this is a non-randomized observational study and therefore at risk of potential biases such as confounding. Although known, clinically relevant confounders were adjusted for, outcomes may have been subject to bias due to unknown factors. In addition, response bias may have impacted the findings, as patients who returned the 18-month questionnaire were marginally older, less likely to smoke, and, perhaps most importantly, were less likely have experienced complications including implant loss at 3 months than the non-responders.

Table 5 Adjusted mean differences in BREAST Q domain scores compared with patients undergoing submuscular reconstruction

|                | Adjusted mean difference in score | P       |
|----------------|----------------------------------|---------|
| **Satisfaction with breasts (n = 801)** |                                   |         |
| Dermal sling   | 0.66 (−0.29, 5.61)               | 0.79    |
| Biological mesh| 2.56 (−1.67, 6.78)               | 0.24    |
| Synthetic mesh | 0.61 (−1.46, 5.79)               | 0.82    |
| Prepectoral    | 6.63 (1.65, 11.61)               | 0.009   |
| Other/different per breast | 2.65 (−0.18, 10.17) | 0.49    |
| **Satisfaction with outcome (n = 794)** |                                   |         |
| Dermal sling   | 2.14 (−0.54, 9.71)               | 0.58    |
| Biological mesh| 2.41 (−0.75, 9.56)               | 0.51    |
| Synthetic mesh | 2.72 (−0.07, 10.51)              | 0.49    |
| Prepectoral    | 1.92 (−0.93, 13.22)              | 0.74    |
| Other/different per breast | 3.21 (−0.40, 10.52) | 0.39    |
| **Psychosocial well-being (n = 795)** |                                   |         |
| Dermal sling   | −3.55 (−9.28, 2.17)              | 0.22    |
| Biological mesh| −0.37 (−5.45, 4.72)              | 0.89    |
| Synthetic mesh | −1.82 (−8.01, 4.37)              | 0.57    |
| Prepectoral    | 0.43 (−4.46, 5.32)               | 0.86    |
| Other/different per breast | 0.04 (−9.36, 9.43) | 0.99    |
| **Sexual well-being (n = 591)** |                                   |         |
| Dermal sling   | −3.93 (−11.12, 3.27)             | 0.29    |
| Biological mesh| 1.15 (−5.60, 7.90)               | 0.74    |
| Synthetic mesh | 0.75 (−8.70, 10.20)              | 0.88    |
| Prepectoral    | 0.43 (−14.92, 15.79)             | 0.96    |
| Other/different per breast | −7.88 (−17.24, 1.48) | 0.10    |
| **Physical well-being (n = 797)** |                                   |         |
| Dermal sling   | −1.78 (−6.31, 2.74)              | 0.44    |
| Biological mesh| 1.72 (−1.97, 5.41)               | 0.36    |
| Synthetic mesh | −0.88 (−5.29, 3.54)              | 0.70    |
| Prepectoral    | 1.22 (−0.47, 7.90)               | 0.72    |
| Other/different per breast | 6.20 (0.09, 12.30) | 0.05    |

Values in parentheses are 95 per cent confidence intervals. *Adjusted for age, BMI, smoking status, ASA grade, indication (malignancy or risk reduction), unilateral versus bilateral surgery, mastectomy type (nipple-sparing versus other), 3-month complications, and adjuvant systemic therapies, radiotherapy and axillary surgery. Random-effects analysis included to adjust for clustering by centre.

understand fully the outcomes of prosthetic reconstruction, as agreed in the recently developed core measurement set for IBBR.

Biological and synthetic mesh-assisted IBBR has been introduced with the aim of improving outcomes for patients, but there remains limited PRO evidence to support these claims. The majority of patients having mesh-assisted procedures in this study benefited from a single operation without the need for expansions or further surgery. Although single-stage surgery may benefit healthcare providers by reducing additional treatment costs, offsetting the costs of the mesh itself, it does not appear to improve PROs 18 months after surgery. Furthermore, given the continued uncertainty regarding the safety of biological and synthetic mesh-assisted techniques, urgent work is required to establish whether and how mesh can be used in IBBR to benefit patients.

Prepectoral techniques have recently been reintroduced into practice, with growing popularity among reconstructive surgeons. These data suggest that prepectoral reconstruction may be promising, but high-quality comparative research including long-term clinical and patient-reported outcomes, and late complications such as capsular contracture, is needed. Evaluation of long-term oncological outcomes are also required owing to concerns that the implant and mesh may affect the detection of cancer recurrence. Ideally, a well designed pragmatic RCT is required to establish definitively which reconstructive technique is most clinically and cost effective, and provides the best outcomes for patients. The iBRA RCT acceptability study has suggested that a trial may be feasible and the Best-BRA external pilot study (ISRCTN10081873) will determine whether it is
possible to recruit patients to anRCT comparing prepectoral and subpectoral techniques before progressing to a definitive large-scale trial. Similar RCTs are underway in Europe, and will generate much needed evidence to support practice and policy. Whilst awaiting further evidence, surgeons must be open with patients about the uncertainties in IBBR to help them make informed decisions about their reconstructive options.

Collaborators

Members of the iBRA steering group and the Breast Reconstruction Research Collaborative:

iBRA Steering Group: N. L. P. Barnes, J. M. Blaizeby, O. A. Branford, E. J. Conroy, R. I. Cuttress, M. D. Gardiner, C. Holcombe, A. Jain, K. McEvoy, N. Mills, S. Mylvaganam, S. Potter, J. M. Skillman, E. M. Teasdale, S. Thrush, Z. Tolkien, L. J. Whisker.

Local investigators and members of the Breast Reconstruction Research Collaborative: Airedale General Hospital: P. Christopoulous, V. Fung, C. Murphy, L. Caldón, H. Fatayer, E. Baker, Alltngelvin Area Hospital: R. Johnston; Ashford and St Peter’s Hospitals NHS Foundation Trust: R. Newton, A. Luangsomboon, S. Brieuch, A. Robinson, M. Runkel, Barts Health NHS Trust: D. Zheng, F. Tsang, L. Johnson, A. Peel, S. Lewedige, S. Barker, J. Hu, V. Vovynov, G. Exarchos, N. Jiwa; Barnsley Hospital NHS Foundation Trust: O. S. Olayinka, J. R. Dick; Basingstoke and North Hampshire Hospital: V. Kalles, K. Harris; Bedford Hospital NHS Trust: N. Manoloudakis, H. Charfare, F. Conroy; Belfast City Hospital: G. Dobson, S. Sloan, G. Irwin, L. Darragh, S. McIntosh, S. Relfs, S. Dawson; Blackpool Teaching Hospitals NHS Foundation Trust: I. Michalak, D. Debath, N. Geerthan, P. Kiruparan; Bradford Teaching Hospitals NHS Foundation Trust: S. Hignett, E. Baker, C. Tait, R. Linforth, M. Salab, K. Rigby; Brighton and Sussex University Hospitals NHS Trust: S. Shaheed, F. Ugolini, R. Rathinaiheesh, C. Zammit, H. Osman, A. Chouhan; Castle Hill Hospital, Hull: A. Wilkins, B. Wooelr, P. Kneeshaw, T. K. Mahapatra, E. Khalifa, K. Groover, K. Hodgkins, S. Harrison, P. McManus, E. Malidis, J. Robinson, F. Langlands; Cheshfield Royal Hospital: F. Mazari, J. Massey, I. Azmy, C. Hollywood, Countess of Chester Hospital: W. Hamilton-Burke, H. Lennon, C. Harding-Mackean, County Durham and Darlington NHS Foundation Trust: T. Collin, J. Henton, Craigavon Area Hospital: G. Irwin, P. Malloin, Diana Princess of Wales Hospital, Grimsby: J. Smith, T. Masudi, S. Joglekar; Dorset County Hospital: K. Kennedy, T. Graja, C. Osborne, R. Sutaria, M. Youssef, T. Stringfield; Dunedin Hospital: B. Smith, East Lancashire Teaching Hospitals: A. Topps, M. Amantia, S. Gawne, J. McNicholos, C. Thomas, M. Khanbhiai, R. Brindle, N. Taheri, R. Kuruvilla, M. Saleh, B. Fux, P. Fugh, J. Idoon, East Surrey Hospital: E. J. Turner, S. Waheed, Frimley Park Hospital: D. Egbeare, J. Stevens, E. Malidis, R. Daoud, I. Karat, I. Laidlaw, H. Osman, K. Kanasalingam, R. Johnson, R. Gurung, Glenfield Hospital, Leicester: K. Lambert, S. Pilgrim, T. Rattay, H. Khout, D. Appleton, B. Vijaynagar, S. Bains, M. Kaushik, J. Krupa; Great Western Hospitals, Swindon: I. Dash, S. Cawthorn, J. Cook, S. Govindarajulu; North Middlesex University Hospital: T. Gandamihardja; Nottingham Breast Unit: L. Brock, M. Akerlund, C. Otierno, A. Halka, R. D. Macmillan, K. Asgeirsson, L. Whisker, H. Khout, T. Rasheed, C. Laban, E. Gutteridge, S. McCulley;

Oxford University Hospitals: D. Remondos, P. J. Roy; Peterborough City Hospital: E. Popa, S. Goh, G. Shetty; Poole General Hospital: S. Clark, A. Evans; Prince Philip Hospital: S. Udayasankar, S. Kavwaja, S. Sharaia; The New QEI Hospital, Welwyn Garden City: T. Walsh, H. Deol; Royal Berkshire Hospital: N. Dunne, B. Smith, A. Hakim; Royal Bolton Hospital: A. Volleamere, C. Garnsey, C. Wright; Royal Bournemouth Hospital: E. Skene; C. Laban, A. Iskender, D. Perry; Royal Devon and Exeter NHS Foundation Trust: D. Egbeare, M. Wiltsher, R. Johnston, D. Ferguson, S. Olsen, R. Tillett, M. Youssef; Royal Glamorgan Hospital: S. Datta, G. Patel, C. Steventon, R. Foulkes, E. Vaughan Williams, G. Osborn, C. Gateley; Royal Hampshire County Hospital, Winchester: N. Chand, B. Zeidain, D. Rainsbury, S. Laws, L. Peiris, K. Harris, V. Kelle; Royal Liverpool and Broadgreen University Hospitals: A. Hargreaves, J. Henderson, T. Kiernan, N. Barnes, M. Chandrashekar, A. Tansley, C. Holcombe, G. Mitchell, R. Little, S. Bathla, M. Pennick, E. De Sousa, W. Harman-Burke; Royal Marsden Hospital: R. Di Micco, R. O’Connell, V. Vovynov, A. Parvaiz, A. Conway, P. Barry, G. Gui, J. Rusby, N. Roche, K. Ramsey, K. Krupa, L. Johnson, D. Elfadil, F. MacNeil, A. Pappe, L. Soldan, I. Hamo, P. Harris, A. August, C. Constantinoiu, A. R. Godden; Royal Surrey County Hospital: E. Clayton, A. Wood, S. Irvine, P. Partlett, F. Pakzad; Royal United Hospital, Bath: R. Shah, I. Dash, S. Potter, J. McIntosh, R. Sutton, N. Laurence; Royal Victoria Infirmary, Newcastle: L. Darragh, J. O’Donoghue, S. Nicholson, H. Cain, N. Collins, J. Chatterjee, A. Critchley, L. Caldón; St James’s University Hospital, Leeds: B. Kim, D. Remondos, J. Massey, R. Achuthan, C. Fenn, B. Mazi, C. Navin, K. Horgan, S. McKenzie, P. Turton, M. L Lansdown, St George’s Hospital, London: S. Tang, D. Banerjee, S. T’s Mary’s Hospital, Isle of Wight: M. Jobson; Salisbury District Hospital: I. Masood, V. Brown, G. Murphy; Sheffield Teaching Hospitals NHS Foundation Trust: V. Fung, N. Dunne, L. Wyld, S. Kohilhardt, V. Chandran, M. Ramada, L. Cauldon, M. Reed, A. Ismail; University Hospital Southampton: S. Robertson, R. Cutress, T. Borsay and South Devon NHS Foundation Trust: C. Ives, M. Green; University College Hospital, London: L. Johnson, R. Carpenter, J. Gattuso, J. Franks; University Hospitals Birmingham: S. Mylvaganam, R. Warner, L. MacLenann, J. Dickson, R. Waters, N. Basu, S. Thomas, S. Tadiapathi, S. Aggarwal; University Hospital Coventry and Warwickshire: A. Carbono, J. Skillman, T. Challoner, S. Parker, A. Park, A. Tomlin, H. Khan, E. Hilti, G. Kishore, R. Nangalia, S. Chambers, S. Ayani; University Hospital Llandough: C. Thomas, R. Foulkes, A. Hussain, J. Idoon, H. Sweetland, E. Davies, S. Tate, S. Goyal, A. Ghattura, C. Zabkiewicz; University Hospitals North Manchester: S. Narayan, S. Souman, D. Archampong, E. Reel; University Hospitals North Staffordshire: S. Narayan, S. Souman, V. Vovynov; University Hospitals South Manchester: J. Henderson, N. Barnes, R. Shotton, R. Johnson, A. Gandhi, J. Harvey, C. Kirwan, J. Murphy, G. Byrne, D. El Shariief, B. Baker, R. Chattopadhyay, S. Chatterjee, R. Irri, M. J. Hwang, K. Williams, L. Barr, Warrington...
and Halton Hospitals: N. Sarfraz, P. Thawdar, Warwick Hospital: M. Dakka, H. Tafazal, L. Jones, D. Enver, D. Clarke, S. Harries; West Hertfordshire NHS Trust: D. Cocker, S. Monib, L. M. Lai, S. Thomson, K. Chong, S. Baldota, J. Maalo; Whiston Hospital: N. Barnes, T. Kiernan, R. Clifford, M. Pennick, L. Chagla, A. Iqbal; Wirral University Teaching Hospital NHS Foundation Trust: R. Vinayagam, J. Lund, M. Callaghan, S. Poonawalla, K. James; Worcestershire Royal Hospital: M. Tan, R. Athwal, M. Mullan, S. Thrush, R. Bright-Thomas, J. Taylor, H. Tafazal, K. McEvoy, M. Ahmed; Yeovil District Hospital: N. Dobner, C. Osborne; York Teaching Hospital NHS Foundation Trust: J. Piper, E. Baker, R. Nasr.

Acknowledgements

This study was registered as ISRCTN37664281. The protocol was published in 2016 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154059/) and prespecified the planned analyses that were to be undertaken. This manuscript reports prespecified analysis of the 18-month PRO data.

This work was funded by a National Institute for Health Research (NIHR) Research for Patient Benefit Programme Grant (PB-PG-0214-33065), pump-priming funding from the Association of Breast Surgery and the British Association of Plastic Reconstructive and Aesthetic Surgeons, and a Research Development Award from the Association of Breast Surgery (2019). S.P. is an NIHR Clinician Scientist (CS-2016-16-019).

This work was undertaken with the support of the Medical Research Council ConDuCT-II (Collaboration and innovation for Difficult and Complex randomised controlled Trials In Invasive procedures) Hub for Trials Methodology Research (MR/K025643/1) and the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care.

Disclosure: The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online

References

1. World Cancer Research Fund. Breast Cancer Statistics. https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics (accessed 1 June 2020)
2. Jeevan R, Browne J, van der Meulen J, Pereira J, Caddy C, Sheppard C et al. First Annual Report of the National Mastectomy and Breast Reconstruction Audit 2008. Leeds: The NHS Information Centre, 2008
3. American Cancer Society. Breast Cancer Facts & Figures 2019–2020. Atlanta: American Cancer Society, 2019
4. National Institute for Health and Care Excellence. Early and Locally Advanced Breast Cancer: Diagnosis and Management. NICE Guidance NG101. 2018. https://www.nice.org.uk/guidance/ng101 (accessed 13 October 2019)
5. Harcourt D, Rumsey N. Psychological aspects of breast reconstruction: a review of the literature. J Adv Nurs 2001; 35: 477–87
6. Jeevan R, Cromwell D, Browne J, van der Meulen J, Pereira J, Caddy C. Second Annual Report of the National Mastectomy and Breast Reconstruction Audit 2009. Leeds: The NHS Information Centre, 2009
7. Mennie JC, Mohanna P-N, O’Donoghue JM, Rainsbury R, Cromwell DA. National trends in immediate and delayed post-mastectomy reconstruction procedures in England: a seven-year population-based cohort study. Eur J Surg Oncol 2017; 43: 52–61
8. Albornoz CR, Bach PB, Mehrara BJ, Dias JJ, Pusic AL, McCarthy CM et al. A paradigm shift in US breast reconstruction: increasing implant rates. Plast Reconstr Surg 2013; 131: 15–23
9. Cordeiro PG. Breast reconstruction after surgery for breast cancer. N Engl J Med 2008; 359: 1590–1601
10. Thiruchelvam PTR, McNeill F, Jallali N, Harris P, Hogan K. Post-mastectomy breast reconstruction. BMJ 2013; 347: f5903
11. Kronowitz SJ, Kuerer HM. Advances and surgical decision-making for breast reconstruction. Cancer 2006; 107: 893–907
12. Sheflan M, Brown I. Immediate implant-based breast reconstruction using variable lower pole support. In: C Urban, M Rietjens (eds), Oncoplastic and Reconstructive Breast Surgery. Milan: Springer, 2013, 235–252
13. Potter S, Conroy EJ, Cutress RI, Williamon FR, Whisker L, Thrush S et al. Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study. Lancet Oncol 2019; 20: 254–266
14. Gamboa-Bobadilla GM. Implant breast reconstruction using acellular dermal matrix. Ann Plast Surg 2006; 56: 22–25
15. Cassileth I, Kohanzadeh S, Amersi F. One-stage immediate breast reconstruction with implants: a new option for immediate reconstruction. Ann Plast Surg 2012; 69: 134–138
16. Zienowicz RJ, Karacaglug E. Implant-based breast reconstruction with alloplast. Plast Reconstr Surg 2007; 120: 373–381
17. Tasoulis M-K, Iqbal FM, Cawthorn S, MacNeill F, Vidya R. Subcutaneous implant breast reconstruction: time to reconsider? Eur J Surg Oncol 2017; 43: 1636–1646
18. Hallberg H, Rafnsdottir S, Selviggi G, Strandell A, Samuelsson O, Stadig I et al. Benefits and risks with acellular dermal matrix (ADM) and mesh support in immediate breast reconstruction: a systematic review and meta-analysis. J Plast Surg Hand Surg 2018; 52: 130–147
19. Potter S, Browning D, Savovic J, Holcombe C, Blazey JM. Systematic review and critical appraisal of the impact of acellular dermal matrix use on the outcomes of implant-based breast reconstruction. Br J Surg 2015; 102: 1010–1025
20. Dikmans REG, Negenborn VL, Bouman M-B, Winters HAH, Twisk JWR, Ruhé PQ et al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial. Lancet Oncol 2017; 18: 251–258
21. Potter S, Wilson RL, Harvey J, Holcombe C, Kirwan CC. Results from the BRIOS randomised trial. Lancet Oncol 2017; 18: e189
22. Sorkin M, Qi J, Kim HM, Hamill JB, Kozlow JH, Pusic AL et al. Acellular dermal matrix in immediate expander/implant breast reconstruction: a multicenter assessment of risks and benefits. Plast Reconstr Surg 2017; 140: 1091–1100
23. Srinivasa DR, Garvey PB, Qi J, Hamill JB, Kim HM, Pusic AL et al. Direct-to-implant versus two-stage tissue expander/implant reconstruction: 2-year risks and patient-reported outcomes from a prospective, multicenter study. Plast Reconstr Surg 2017; 140: 869–877
24. Walia GS, Aston J, Bello R, Mackert GA, Pedreira RA, Cho BH et al. Prepectoral versus subpectoral tissue expander placement: a
clinical and quality of life outcomes study. Plast Reconstr Surg Glob Open 2018; 6:e1731
25. Casella D, Di Taranto G, Onesti MG, Greco M, Ribuffo D. A retrospective comparative analysis of risk factors and outcomes in direct-to-implant and two-stages prepectoral breast reconstruction: BMI and radiotherapy as new selection criteria of patients. Eur J Surg Oncol 2019; 45:1357–1363
26. Negenborn VL, Young-Afat DA, Dikmans REG, Smit JM, Winters HAH, Groat JPW et al. Quality of life and patient satisfaction after one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage breast reconstruction (BRIOS): primary outcome of a randomised, controlled trial. Lancet Oncol 2018; 19:1205–1214
27. Potter S, Conroy EJ, Williamson PR, Thrush S, Whisker LJ, Skillman JM et al. The iBRA (implant breast reconstruction evaluation) study: protocol for a prospective multi-centre cohort study to inform the feasibility, design and conduct of a pragmatic randomised clinical trial comparing new techniques of implant-based breast reconstruction. Pilot Feasibility Stud 2016; 2:41
28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–381
29. Medical Research Council Regulatory Support Centre, Health Research Authority. Health Research Authority Decision Tool. http://www.hra-decisiontools.org.uk/research/ (accessed 24 October 2019)
30. Memorial Sloan Kettering Cancer Center, University of British Columbia. BREAST-Q | Cancer Version 1.0. http://qportfolio.org/score-breast-q-breast-cancer-2/ (21 August 2019)
31. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg 2009; 124:345–353
32. Cano SJ, Klassen AF, Scott AM, Cordeiro PG, Pusic AL. The BREAST-Q: further validation in independent clinical samples. Plast Reconstr Surg 2012; 129:293–302
33. Potter S, Holcombe C, Ward JA, Blazey JM, Brookes ST, Cawthorn SJ et al. Development of a core outcome set for research and audit studies in reconstructive breast surgery. Br J Surg 2015; 102:1360–1371
34. Jeevan R, Cromwell DA, Browne JP, Caddy CM, Pereira J, Sheppard C et al. Findings of a national comparative audit of mastectomy and breast reconstruction surgery in England. J Plast Reconstr Aesthet Surg 2014; 67:1333–1344
35. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453–1457
36. Rainsbury D, Willett A (eds). Oncoplastic Breast Reconstruction. Guidelines for Best Practice; 2012. http://www.bapras.org.uk/docs/default-source/commissioning-and-policy/final-oncoplastic-guidelines—healthcare-professionals.pdf?sfvrsn=0 (accessed 2 October 2019)
37. Jeevan R, Cromwell D, Browne J, van der Meulen J, Pereira J, Caddy C et al. National Mastectomy and Breast Reconstruction Audit 2011. Leeds: The NHS Information Centre, 2011
38. Voineskos SH, Klassen AF, Cano SJ, Pusic AL, Gibbons CJ. Giving meaning to differences in BREAST-Q scores: minimal important difference for breast reconstruction patients. Plast Reconstr Surg 2019; 145:11e–20e
39. Chadarana M, Harries S. Multicentre study of prepectoral breast reconstruction using acellular dermal matrix. BJS Open 2020; 4:71–77
40. Rebowe RE, Alired LJ, Nahabedian MY. The evolution from subcutaneous to prepectoral prosthetic breast reconstruction. Plast Reconstr Surg Glob Open 2018; 6:e1797
41. Vidya R, Berna G, Sbitany H, Nahabedian M, Becker H, Reitsamer R et al. Prepectoral implant-based breast reconstruction: a joint consensus guide from UK, European and USA breast and plastic reconstructive surgeons. Ecanermedicalscei 2019; 13:927
42. Liu J, Hou J, Li Z, Wang B, Sun J. Efficacy of a cellular dermal matrix in capsular contracture of implant-based breast reconstruction: a single-arm meta-analysis. Aesthetic Plast Surg 2020; 44:735–742
43. Potter S, Davies C, Holcombe C, Weiler-Mithoff E, Skillman J, Vidya R et al. International development and implementation of a core measurement set for research and audit studies in implant-based breast reconstruction: a study protocol. BMJ Open 2020; 10:e035505
44. Potter S, MacKenzie M, Blazey JM. Does the addition of mesh improve outcomes in implant based breast reconstruction after mastectomy for breast cancer? BMJ 2018; 362:k2607
45. Davies G, Mills N, Holcombe C, Potter S, Barnes NLP, Blazey JM et al. Perceived barriers to randomised controlled trials in breast reconstruction: obstacle to trial initiation or opportunity to resolve? A qualitative study. Trials 2020; 21:316